News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
144,917 Results
Type
Article (7878)
Company Profile (80)
Press Release (136959)
Multimedia
Podcasts (16)
Webinars (2)
Section
Business (44842)
Career Advice (95)
Deals (6952)
Drug Delivery (18)
Drug Development (26087)
Employer Resources (14)
FDA (3646)
Job Trends (3895)
News (79654)
Policy (5491)
Tag
2024 BioCapital Digital (4)
2024 BioForest Digital (1)
2024 BioMidwest Digital (1)
2024 Bio NC Digital (2)
2024 Biotech Bay Standard (1)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (3)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (355)
Accelerated approval (1)
Adcomms (11)
Allergies (4)
Alliances (13286)
ALS (9)
Alzheimer's disease (192)
Antibody-drug conjugate (ADC) (94)
Approvals (3683)
Artificial intelligence (86)
Autoimmune disease (4)
Automation (3)
Bankruptcy (55)
Best Places to Work (3519)
BIOSECURE Act (1)
Biosimilars (36)
Biotechnology (62)
Bladder cancer (54)
Brain cancer (22)
Breast cancer (192)
Cancer (1543)
Cardiovascular disease (19)
Career advice (82)
Career pathing (3)
CAR-T (73)
Cell therapy (191)
Cervical cancer (12)
Clinical research (21785)
Collaboration (346)
Compensation (114)
Complete response letters (1)
COVID-19 (355)
CRISPR (15)
C-suite (93)
Cystic fibrosis (4)
Data (749)
Decentralized trials (1)
Denatured (4)
Depression (6)
Diabetes (50)
Diagnostics (1424)
Digital health (3)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (43)
Drug pricing (10)
Drug shortages (4)
Duchenne muscular dystrophy (6)
Earnings (15578)
Editorial (9)
Employer branding (3)
Employer resources (15)
Events (25752)
Executive appointments (246)
FDA (3983)
Featured Employer (13)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (2)
Funding (175)
Gene editing (25)
Generative AI (8)
Gene therapy (89)
GLP-1 (114)
Government (550)
Guidances (13)
Healthcare (4420)
Huntington's disease (4)
IgA nephropathy (5)
Immunology and inflammation (32)
Indications (12)
Infectious disease (385)
Inflammatory bowel disease (29)
Inflation Reduction Act (2)
Influenza (13)
Intellectual property (24)
Interviews (11)
IPO (3328)
IRA (8)
Job creations (574)
Job search strategy (74)
Kidney cancer (10)
Labor market (3)
Layoffs (154)
Leadership (3)
Legal (626)
Liver cancer (40)
Lung cancer (251)
Lymphoma (78)
Management (3)
Manufacturing (94)
MASH (7)
Medical device (1282)
Medtech (1282)
Mergers & acquisitions (3781)
Metabolic disorders (90)
Multiple sclerosis (9)
NASH (1)
Neurodegenerative disease (7)
Neuropsychiatric disorders (2)
Neuroscience (281)
NextGen: Class of 2025 (1112)
Non-profit (544)
Northern California (801)
Now hiring (8)
Obesity (34)
Opinion (36)
Ovarian cancer (58)
Pain (6)
Pancreatic cancer (56)
Parkinson's disease (23)
Partnered (3)
Patents (45)
Patient recruitment (31)
Peanut (3)
People (14420)
Pharmaceutical (19)
Pharmacy benefit managers (1)
Phase I (7956)
Phase II (9252)
Phase III (7092)
Pipeline (413)
Policy (17)
Postmarket research (577)
Preclinical (2602)
Press Release (7)
Prostate cancer (70)
Psychedelics (2)
Radiopharmaceuticals (171)
Rare diseases (71)
Real estate (1171)
Recruiting (6)
Regulatory (4842)
Reports (11)
Research institute (691)
Resumes & cover letters (13)
Rett syndrome (4)
RSV (10)
Schizophrenia (22)
Series A (39)
Series B (10)
Service/supplier (5)
Sickle cell disease (22)
Southern California (688)
Special edition (1)
Spinal muscular atrophy (17)
Sponsored (3)
Startups (828)
State (2)
Stomach cancer (10)
Supply chain (10)
Tariffs (2)
The Weekly (12)
United States (6378)
Vaccines (129)
Venture capitalists (13)
Weight loss (18)
Women's health (1)
Date
Today (34)
Last 7 days (124)
Last 30 days (713)
Last 365 days (9947)
2025 (2784)
2024 (10618)
2023 (11903)
2022 (14392)
2021 (14647)
2020 (12256)
2019 (9626)
2018 (7159)
2017 (7967)
2016 (6970)
2015 (7712)
2014 (5092)
2013 (3673)
2012 (3980)
2011 (3957)
2010 (4204)
Location
Africa (93)
Alabama (20)
Alaska (1)
Arizona (24)
Arkansas (3)
Asia (11981)
Australia (1550)
California (1724)
Canada (496)
China (267)
Colorado (61)
Connecticut (88)
Delaware (98)
Europe (21663)
Florida (270)
Georgia (14)
Idaho (6)
Illinois (163)
India (9)
Indiana (54)
Iowa (2)
Japan (72)
Kansas (16)
Kentucky (10)
Maine (6)
Maryland (282)
Massachusetts (1429)
Michigan (19)
Minnesota (68)
Missouri (8)
Montana (5)
Nebraska (2)
Nevada (7)
New Hampshire (8)
New Jersey (487)
New Mexico (4)
New York (517)
North Carolina (192)
North Dakota (3)
Northern California (801)
Ohio (85)
Oklahoma (8)
Oregon (6)
Pennsylvania (284)
Puerto Rico (1)
Rhode Island (4)
South America (129)
South Carolina (2)
Southern California (688)
Tennessee (15)
Texas (292)
Utah (43)
Virginia (21)
Washington D.C. (6)
Washington State (200)
Wisconsin (13)
144,917 Results for "cg oncology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Bladder cancer
Protara, CG Oncology Tout Promising Bladder Cancer Outcomes
Protara is advancing a cell therapy that triggers both adaptive and innate antitumor immune responses, while CG Oncology’s approach makes use of an oncolytic immunotherapy that preferentially targets cancer cells and proliferates inside them, destroying them from the inside.
December 6, 2024
·
2 min read
·
Tristan Manalac
Press Releases
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
March 31, 2025
·
11 min read
Press Releases
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
April 1, 2025
·
4 min read
Press Releases
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
February 26, 2025
·
1 min read
Press Releases
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
March 12, 2025
·
3 min read
Biotech Beach
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
CG Oncology, Inc. announced that it has initiated an Expanded Access Program for cretostimogene grenadenorepvec in the U.S. for patients with Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette-Guerin and meet certain program eligibility criteria.
June 18, 2024
·
5 min read
Drug Development
CG Oncology Touts Bladder Cancer Complete Response Rate for Immunotherapy
Following an upsized IPO earlier this year, CG Oncology on Friday posted promising Phase III data for cretostimogene, which elicited a 75% complete response rate in high-risk non-muscle invasive bladder cancer patients.
May 6, 2024
·
2 min read
·
Tristan Manalac
Press Releases
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 17, 2024
·
2 min read
Press Releases
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
November 20, 2024
·
5 min read
Biotech Beach
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
CG Oncology, Inc., a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, will host a virtual investor event on Friday, May 3, 2024, at 4:30pm EDT.
April 26, 2024
·
2 min read
1 of 14,492
Next
